Autologous BCMA/TACI-targeted Trimeric APRIL-based CAR T Cells - CISMeF
Autologous BCMA/TACI-targeted Trimeric APRIL-based CAR T CellsNCIt concept
Preferred Label : Autologous BCMA/TACI-targeted Trimeric APRIL-based CAR T Cells;
NCIt synonyms : Autologous Anti-BCMA/TACI Trimeric APRIL-based CAR-T Cells; Autologous Anti-BCMA/Anti-TACI Trimeric APRIL-based CAR T-cells; TriPRIL CAR T Cells;
NCIt definition : A preparation of autologous T-lymphocytes that are genetically engineered to contain
a dual-targeted chimeric antigen receptor (CAR), which includes a trimeric form of
the natural protein a proliferation-inducing ligand (APRIL; TNFSF13), that targets
the tumor-associated antigens (TAAs) B-cell maturation antigen (BCMA; TNFRSF17) and
transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI;
TNFRSF13B), with potential immunomodulating and antineoplastic activities. Upon administration,
the autologous BCMA/TACI-targeted trimeric APRIL-based CAR T cells bind to BCMA and
TACI expressed on tumor cells and induce selective cytotoxicity in those cells. BCMA
and TACI, receptors for both APRIL and B-cell activating factor (BAFF), are members
of the tumor necrosis factor receptor superfamily (TNFRSF). They are both found on
the surfaces of plasma cells, overexpressed on malignant plasma cells and play key
roles in plasma cell proliferation and survival. The incorporation of the trimeric,
natural conformation of APRIL into the CAR enhances the binding to BCMA and TACI compared
with the monomeric form of APRIL.;